Literature DB >> 23146957

X chromosome inactivation pattern in BRCA gene mutation carriers.

Siranoush Manoukian1, Paolo Verderio, Silvia Tabano, Patrizia Colapietro, Sara Pizzamiglio, Francesca R Grati, Mariarosaria Calvello, Bernard Peissel, John Burn, Valeria Pensotti, Claudia Allemani, Silva M Sirchia, Paolo Radice, Monica Miozzo.   

Abstract

An association of preferential X chromosome inactivation (XCI) with BRCA gene status and breast/ovarian cancer risk has been reported. We evaluated XCI in a large group of BRCA mutation carriers compared to non-carriers and investigated associations between preferential XCI (⩾90:10) and age, mutated gene, cancer development and chemotherapy. XCI was analysed by human androgen receptor (HUMARA) assay and pyrosequencing in 437 BRCA1 or BRCA2 mutation carriers and 445 age-matched controls. The distribution of XCI patterns in the two groups was compared by logistic regression analysis. The association between preferential XCI and selected variables was investigated in both univariate and multivariate fashion. In univariate analyses preferential XCI was not significantly associated with the probability of being a BRCA mutation carrier, nor with cancer status, whereas chemotherapeutic regime and age both showed a significant association. In multivariate analysis only age maintained significance (odds ratio, 1.056; 95% confidence interval, 1.016-1.096). Our findings do not support the usefulness of XCI analysis for the identification of BRCA mutation carriers and cancer risk assessment. The increasing preferential XCI frequency with ageing and the association with chemotherapy justify extending the investigation to other categories of female cancer patients to identify possible X-linked loci implicated in cell survival.
Copyright © 2012 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23146957     DOI: 10.1016/j.ejca.2012.10.013

Source DB:  PubMed          Journal:  Eur J Cancer        ISSN: 0959-8049            Impact factor:   9.162


  7 in total

1.  Molecular signatures of X chromosome inactivation and associations with clinical outcomes in epithelial ovarian cancer.

Authors:  Stacey J Winham; Nicholas B Larson; Sebastian M Armasu; Zachary C Fogarty; Melissa C Larson; Brian M McCauley; Chen Wang; Kate Lawrenson; Simon Gayther; Julie M Cunningham; Brooke L Fridley; Ellen L Goode
Journal:  Hum Mol Genet       Date:  2019-04-15       Impact factor: 6.150

2.  Preferential X Chromosome Inactivation as a Mechanism to Explain Female Preponderance in Myasthenia Gravis.

Authors:  Vanessa Nicolì; Silvia Maria Tabano; Patrizia Colapietro; Michelangelo Maestri; Roberta Ricciardi; Andrea Stoccoro; Laura Fontana; Melania Guida; Monica Miozzo; Fabio Coppedè; Lucia Migliore
Journal:  Genes (Basel)       Date:  2022-04-15       Impact factor: 4.141

3.  An integrative approach to assess X-chromosome inactivation using allele-specific expression with applications to epithelial ovarian cancer.

Authors:  Nicholas B Larson; Zachary C Fogarty; Melissa C Larson; Kimberly R Kalli; Kate Lawrenson; Simon Gayther; Brooke L Fridley; Ellen L Goode; Stacey J Winham
Journal:  Genet Epidemiol       Date:  2017-11-08       Impact factor: 2.135

4.  Dysregulation of X chromosome inactivation in high grade ovarian serous adenocarcinoma.

Authors:  Jun Kang; Hee Jin Lee; Jiyoung Kim; Jae Jun Lee; Lee-so Maeng
Journal:  PLoS One       Date:  2015-03-05       Impact factor: 3.240

5.  XIST Induced by JPX Suppresses Hepatocellular Carcinoma by Sponging miR-155-5p.

Authors:  Xiu Qing Lin; Zhi Ming Huang; Xin Chen; Fang Wu; Wei Wu
Journal:  Yonsei Med J       Date:  2018-09       Impact factor: 2.759

6.  (Epi)genetic profiling of extraembryonic and postnatal tissues from female monozygotic twins discordant for Beckwith-Wiedemann syndrome.

Authors:  Laura Fontana; Maria F Bedeschi; Giulia A Cagnoli; Jole Costanza; Nicola Persico; Silvana Gangi; Matteo Porro; Paola F Ajmone; Patrizia Colapietro; Carlo Santaniello; Milena Crippa; Silvia M Sirchia; Monica Miozzo; Silvia Tabano
Journal:  Mol Genet Genomic Med       Date:  2020-07-06       Impact factor: 2.183

7.  Transmission of X-linked Ovarian Cancer: Characterization and Implications.

Authors:  John Lewis Etter; Kirsten Moysich; Shaun Kohli; Shashikant Lele; Kunle Odunsi; Kevin H Eng
Journal:  Diagnostics (Basel)       Date:  2020-02-07
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.